RNase Control Market size is poised to reach USD 603 Million by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of RNase control was USD 209 Million. The reason behind the growth is due to the growing cases of HIV across the globe. One of the biggest threats to global health and development is HIV, driven by the use of tainted injecting equipment and unprotected intercourse between prostitutes and their clients. According to the World Health Organization (WHO), in 2022, the predicted global number of individuals living with HIV was 39 million.
The growing advancements in RNase technology are believed to fuel the RNase control market growth. Among the significant advancements is the identification of the RNase L signaling route which has been connected to inherited prostate cancer as well as antiviral and antibacterial protection to include possible therapeutic targets for the creation of antibacterial drugs.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~8% |
|
Base Year Market Size (2023) |
~ USD 209 Million |
|
Forecast Year Market Size (2036) |
~ USD 603 Million |
|
Regional Scope |
|
Product Type (Recombinant, Non-Recombinant)
The recombinant segment in the RNase control market is estimated to gain a robust revenue share of 55% in the coming years owing to the growing burden of pancreatic cancer across the globe as a result of rising population length and aging. For instance, pancreatic cancer (PC) is an extremely deadly cancer with a three-year overall survival rate varying from over 0.4% to 8% in Europe. Particularly, there will be a more than 25% increase in cases overall in the EU by 2040.
In the field of cancer, therapies have been a revolution because of recombinant DNA technologies that have the potential to treat cancer. Moreover, TRAIL-Mu3, a recombinant protein, strengthens the apoptotic signaling pathway in pancreatic cancer cells as defects in the apoptotic pathway can lead to cancer cell resistance. This may drive the demand for RNase inhibitors a recombinant protein that specifically inhibits ribonucleases that have anticancer activity and are known to demonstrate various methods of destroying cancer cells.
Application (RNase Control that Inhibits A Family, RNase Control that Inhibits Other Than A Family)
The RNase control that inhibits the other than A family segment in the RNase control market is set to garner a notable share shortly. Ribonucleases A, B, and C are precisely inhibited by RNase Inhibitor, a recombinant protein that is extracted from a strain of Escherichia coli. Escherichia coli is still the most popular and economical microbial factory for recombinant protein production that can be effectively achieved by employing lactose as an inducer. Moreover, in Escherichia coli, the endoribonuclease RNase E is crucial for the processing and destruction of RNA since it restricts RNase E overproduction and can boost its synthesis when this concentration falls below normal.
Our in-depth analysis of the global RNase control market includes the following segments:
|
Product Type |
|
|
End-User |
|
|
Application |
|
North American Market Forecast
RNase control market in North America is predicted to account for the largest share of 44% by 2036 impelled by the growing number of clinical trials. As a result, more RNases are being examined which have the potential to demonstrate the enormous promise of RNA-based medications for the treatment of a wide range of ailments. For instance, the United States had more than 38,835 ongoing clinical trials as of January 2023.
European Market Statistics
The Europe RNase control market is estimated to be the second largest, during the forecast period led by the increasing usage and development of biotechnology and the life sciences to help the globe address its most important sustainability and health issues. Moreover, with more than 40% of the world's top 100 universities in the life sciences and around 30% of the top 100 in computer science, the region is a continent with significant scientific strengths.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?